DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Albert Bourla - 1 Michael Ganio - 1 Michael Erman - 1 Aurora Ellis - 1 Rocky - 1 Sriparna Roy - 1 Shailesh - 1
Top related locs:
North Carolina Rocky Mount U.S Bengaluru
Top related orgs:
Drugmaker Pfizer Inc - 2 Pfizer - 2 Thomson - 2 YORK - 1 American Society of Health - 1 System - 1 ABC - 1 WTVD - 1

Search resuls for: "Drugmaker Pfizer Inc"


11 mentions found


☆ Pfizer says supply of some drugs may be disrupted after NC tornado
  + stars: | 2023-07-24 | by ( ) www.reuters.com   time to read: +1 min
NEW YORK, July 24 (Reuters) - Drugmaker Pfizer Inc (PFE.N) said over 30 drugs, including injections of painkiller fentanyl and anesthetic lidocaine, may see supply disruption after a tornado destroyed a warehouse at its Rocky Mount, North Carolina, plant last week. The company sent a letter late last week to its hospital customers saying it had identified around 64 different formulations or dosages of those more than 30 drugs produced at the plant that may experience continued or new supply disruptions. The company has placed limits on how much supply of those drugs its customers can buy. It said the list was "based on Pfizer market share and inventory levels of less than 3 months across our Pfizer distribution centers and the wholesale chain." The Rocky Mount plant is one of the largest factories for sterile injectable medicines in the world.
Persons: Albert Bourla, Michael Ganio, Michael Erman, Aurora Ellis Organizations: YORK, Drugmaker Pfizer Inc, Pfizer, American Society of Health, System, Thomson Locations: North Carolina
☆ Pfizer plant in North Carolina damaged by tornado
  + stars: | 2023-07-20 | by ( ) www.reuters.com   time to read: +1 min
[1/4] The roof of a Pfizer facility shows heavy damage after a tornado passed the area in Rocky Mount, North Carolina, U.S. July 19, 2023. July 19 (Reuters) - Drugmaker Pfizer Inc (PFE.N) said on Wednesday its plant in Rocky Mount, North Carolina, which is one of the largest sterile injectable product facilities in the world, has suffered heavy damage from a tornado. A company spokesperson in an emailed statement confirmed that the Rocky Mount facility was damaged and the drugmaker was assessing the situation to determine the impact on production. The Rocky Mountain facility employs over 4,500 professionals, according to Pfizer's website. Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh KuberOur Standards: The Thomson Reuters Trust Principles.
Persons: Rocky, Sriparna Roy, Shailesh Organizations: Pfizer, ABC, WTVD, REUTERS, Drugmaker Pfizer Inc, Thomson Locations: Rocky Mount, North Carolina, U.S, Bengaluru
☆ Pfizer, Valneva to stop testing Lyme disease vaccine in some U.S. patients
  + stars: | 2023-02-17 | by ( Bhanvi Satija | ) www.reuters.com   time to read: +2 min
[1/2] Pfizer company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna GeronFeb 17 (Reuters) - Drugmaker Pfizer Inc (PFE.N) and France's Valneva (VLS.PA) will stop testing a Lyme disease vaccine in roughly half of U.S. patients in a late-stage study, the companies said, citing a breach of clinical trial guidelines by a third-party contractor. Pfizer still expects to submit marketing applications for the experimental vaccine in the United States and Europe in 2025. The trial was expected to include around 6,000 participants aged 5 and older across Europe and United States, where Lyme disease is highly endemic. Paris-listed shares of Valneva fell nearly 10% to 5.72 euros following the news and U.S.-listed shares of Pfizer were down marginally in premarket trading.
☆ Pfizer to sell all its drugs in low-income countries at non-profit price
  + stars: | 2023-01-17 | by ( ) www.reuters.com   time to read: 1 min
Companies Pfizer Inc FollowJan 17 (Reuters) - U.S. drugmaker Pfizer Inc (PFE.N) said on Tuesday it will offer its full portfolio of drugs, including off-patent medicines such as chemotherapies and oral cancer treatments, on a not-for-profit basis to 45 low-income countries in the world. In an expansion of the company's "An Accord for a Healthier World" program, which is aimed at increasing access to innovative treatments in some of the world's poorest countries, Pfizer said it will now offer a total of 500 products. When the drugmaker launched the program in May 2022, it offered only its patented medicines including COVID-19 treatment Paxlovid and its big-selling breast cancer drug, Ibrance, at a not-for-profit price. Reporting by Bhanvi Satija in BengaluruOur Standards: The Thomson Reuters Trust Principles.
☆ U.S. FDA, CDC see early signal of Pfizer bivalent COVID shot's link to stroke
  + stars: | 2023-01-13 | by ( ) www.reuters.com   time to read: +2 min
Jan 13 (Reuters) - A safety monitoring system flagged that U.S. drugmaker Pfizer Inc (PFE.N) and German partner BioNTech's updated COVID-19 shot could be linked to a type of brain stroke in older adults, according to preliminary data analyzed by U.S. health authorities. An ischemic stroke, also known as brain ischemia, is caused by blockages in arteries that carry blood to the brain. "Although the totality of the data currently suggests that it is very unlikely that the signal in VSD (Vaccine Safety Datalink) represents a true clinical risk, we believe it is important to share this information with the public," the health authorities said. Pfizer and BioNTech said in a statement that they have been made aware of limited reports of ischemic strokes in people 65 and older following vaccination with their updated shot. This safety concern has not been identified with Moderna's (MRNA.O) bivalent shot and both the CDC and FDA continue to recommend that everyone aged 6 months and older stay up-to-date with their COVID-19 vaccination.
☆ Pfizer's hemophilia B gene therapy succeeds in late-stage study
  + stars: | 2022-12-29 | by ( ) www.reuters.com   time to read: +1 min
Dec 29 (Reuters) - U.S. drugmaker Pfizer Inc (PFE.N) said on Thursday its experimental gene therapy for the treatment of hemophilia B, a rare inherited blood disorder, met its main goal in a late-stage study. The drugmaker licensed its hemophilia B gene therapy from Roche's (ROG.S) Spark Therapeutics unit in 2014 for a $20-million upfront payment. Pfizer plans to discuss the late-stage data with regulatory authorities in Europe and the United States and share additional data for the experimental therapy at a scientific conference in early 2023. According to government data, the estimated prevalence of hemophilia in the United States is 12 cases per 100,000 males for hemophilia A and 3.7 cases per 100,000 males for hemophilia B. In November, the U.S. health regulator approved the first gene therapy, CSL Ltd and uniQure's Hemgenix, to treat hemophilia B.Pfizer is also testing other experimental gene therapies in late-stage trials as potential treatments for the bleeding disorder hemophilia A and muscular disorder Duchenne muscular dystrophy.
☆ U.S. ready to help China on COVID-19 surge if Beijing asks - White House
  + stars: | 2022-12-14 | by ( ) www.reuters.com   time to read: +1 min
WASHINGTON, Dec 14 (Reuters) - The United States is prepared to help China deal with a surge of COVID-19 infections if Beijing requests assistance, the White House said on Wednesday. John Kirby, the White House national security spokesperson, told reporters that China has not requested help at this stage. "We have made that point that we are prepared to help in any way they might find acceptable. China began shifting away from the "zero COVID" policy just this month, after protests against the economically-damaging curbs that had been championed by President Xi Jinping. The change has spurred concerns about a surge in COVID cases.
☆ Gilead, Kite in process of pausing Twitter advertising
  + stars: | 2022-11-07 | by ( ) www.reuters.com   time to read: +1 min
Nov 7 (Reuters) - Gilead Sciences Inc (GILD.O) said on Monday the company and its unit Kite were in the "process of pausing advertising" on Twitter, after Elon Musk completed his takeover of the social media company. In a statement to Reuters, Gilead said it was monitoring its advertising spend and waiting to better understand how community standards and content moderation will be handled on Twitter now. Gilead joins a growing list of U.S. companies, including General Motors (GM.N) and General Mills (GIS.N), who have either paused or are in the process of re-evaluating advertising on the social media platform. Last week, the Wall Street Journal reported Oreo maker Mondelez International Inc (MDLZ.O) and U.S. drugmaker Pfizer Inc (PFE.N) had also temporarily halted advertising with Twitter. Reporting by Bhanvi Satija and Raghav Mahobe in Bengaluru; Editing by Krishna Chandra EluriOur Standards: The Thomson Reuters Trust Principles.
☆ Scholz secures agreement allowing expats in China to use BioNTech COVID-19 vaccine
  + stars: | 2022-11-04 | by ( Andreas Rinke | ) www.reuters.com   time to read: +1 min
BEIJING, Nov 4 (Reuters) - German Chancellor Olaf Scholz announced an agreement on Friday to let expatriates in China use the COVID-19 vaccine from Germany's BioNTech (22UAy.DE) and pressed for Beijing to allow the shot to be made freely available to Chinese citizens. On his first visit to China since becoming chancellor and the first by a G7 leader since the pandemic, Scholz said China and Germany had different approaches to fighting the virus but had a joint responsibility to eliminate it. The two countries "agreed on close cooperation in the fight against the pandemic," Scholz said in a briefing alongside the Chinese premier Li Keqiang. "This also includes an approval of the BioNTech vaccine for expatriates in China. I hope that the circle of eligible persons can soon be widened to a general free ability of the BioNTech vaccine," said Scholz.
☆ Pfizer, BioNTech start COVID-flu combination vaccine study
  + stars: | 2022-11-03 | by ( ) www.reuters.com   time to read: +1 min
Nov 3 (Reuters) - U.S. drugmaker Pfizer Inc (PFE.N) and its German partner BioNTech SE have started an early-stage study to evaluate a combination vaccine targeting COVID-19 and influenza, the companies said on Thursday. The single-dose vaccine candidate is a combination of Pfizer's mRNA-based flu shot and the companies' Omicron-tailored COVID-19 booster shot. The early-stage study, which is being sponsored by BioNTech, aims to evaluate the combination shot's safety, tolerability and immunogenicity, or the ability to generate immune response. Rivals Moderna Inc (MRNA.O) and Novavax Inc (NVAX.O) are also developing combination vaccines targeting both COVID-19 and influenza. read moreReporting by Bhanvi Satija in Bengaluru; Editing by Savio D'Souza and Vinay DwivediOur Standards: The Thomson Reuters Trust Principles.
☆ Cheerios maker General Mills, Audi of America pause advertising on Twitter
  + stars: | 2022-11-03 | by ( ) www.reuters.com   time to read: +2 min
[1/2] Packages of Cheerios, a brand owned by General Mills, are seen in a store in Manhattan, New York, U.S., November 12, 2021. REUTERS/Andrew KellyNov 3 (Reuters) - General Mills Inc (GIS.N) and Luxury automaker Audi of America said on Thursday they have paused advertising on Twitter, days after the social media platform was acquired by billionaire Elon Musk for $44 billion. "We will continue to monitor this new direction and evaluate our marketing spend," a General Mills spokesperson said. Audi of America, the Herndon, Virginia-based U.S. unit of Audi - a Volkswagen Group (VOWG_p.DE) brand - said it would "continue to evaluate the situation." The two companies join top U.S. automaker General Motors Co (GM.N), which last week said it had temporarily halted paid advertising on Twitter.
0 next >>
Total: 11